Amble Review

What Amble charges

• Sermorelin: $159/mo — the month-to-month rate, read under the seller's own two-word column header "Plan | Per Month" as "1 Month $159", beside "3 Month $149" and "6 Month $135" — ⛔ the two lower figures are PER-MONTH rates that require a 3- or 6-month plan, not plan totals, because the column they sit in says so; nothing here was divided. The separate Sermorelin ODT page publishes the identical three-rung ladder for the oral-dissolving form, so no second row is recorded for it
• NAD+: $199/mo — the month-to-month rate, read under the column header "Plan | Per Month" as "1 Month $199", beside "3 Month $183", "6 Month $167" and "12 Month $125"; ⚠ the sitewide banner on the same page reads "Limited Offer: GLP $150 + NAD $100" with no period attached and no product page repeats it, so this seller shows two NAD+ figures at once
• Glutathione: $100/mo — the month-to-month rate, read under the column header "Plan | Per Month" as "1 Month $100", beside "3 Month $92", "6 Month $83" and "12 Month $75"

Amble also sells 1 compound this site boards without publishing a price for it: Tesamorelin.

A column header that settles the argument

Most sellers publish a plan ladder and leave the reader to work out whether the smaller figures beside the longer terms are monthly rates or prepaid totals. The difference is enormous and the pages almost never say.

This seller says. The ladder sits under a two-word header that names the unit, and each row underneath pairs a plan length with a figure in that unit. There is nothing to convert and no arithmetic that could go wrong.

The same shape repeats on all three priced product pages, which means the three compounds can be compared against each other directly rather than through three different interpretations of three different layouts.

This site records the month-to-month rung, because it is the only one a buyer can reach without committing to a plan term, and writes the whole ladder into the qualifier so nobody later mistakes a discounted rung for the entry price.

Twenty-two pages that look like a catalogue and are not one

The sitemap carries a long run of paths under a peptides directory, one per compound, in exactly the shape a product catalogue takes. Nine of them name compounds this site tracks.

Every one of them renders as a signed editorial article: a breadcrumb, a dateline, a reading-time badge, an author biography. No price, no dose selector, no cart. They are content, not commerce.

Reading the sitemap alone would have credited this seller with nine tracked compounds it does not sell. That is the exact failure a URL-shaped inference produces, and it is why this row declares only what a rendered product page or the seller's own FAQ actually offers.

One further compound is declared without a price, because the seller names it in its own product-page FAQ as an available treatment and publishes no page for it anywhere.

Two figures for one compound, at the same time

A promotional banner is pinned above every page on this host. It names one of the tracked compounds and attaches a figure to it that no product page repeats and that carries no billing period at all.

The product page for that compound publishes a four-rung ladder whose cheapest rung requires a year-long commitment and is still not the banner figure. Both are visible on the same screen at the same time.

This site records the ladder and writes the banner conflict onto the row rather than reconciling them, because both are published, by the same seller, today. A later reader who sees only one of them should not conclude the other was a mistake.

The pharmacy question gets a category and not a name: the FAQ explains what the two classes of compounding facility are regulated by, which is true and tells a buyer nothing about who fills their order.

How we verified this

• Rendered every page in a real browser and read only laid-out, visible text nodes, so nothing was taken from a serialised payload.
• Fired two nonsense paths at the host in the same session before the real pages; both returned an honest not-found response distinct from every real page.
• Compared the requested URL against the effective URL on every fetch and confirmed they matched.
• Opened each of the peptide-directory pages rather than inferring a catalogue from the sitemap, and confirmed each is a dated editorial article with an author byline and no purchase control.
• Read the state-availability answer about the company separately from the licensure claim about its prescribers, and recorded only the first as coverage.
• Recorded the sitewide banner figure as a conflict on the row rather than reconciling it against the product ladder.
• Screened the operating company and the brand against the regulator's live warning-letter index, with a known-positive query and a nonsense query in the same run to prove the search discriminates.